Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2021

Harnessing the potential of multiomics studies for precision
medicine in infectious disease
Rebecca A. Ward
Massachusetts General Hospital

Philip A. Mudd
Washington University School of Medicine in St. Louis

Rachel M. Presti
Washington University School of Medicine in St. Louis

Andrej Spec
Washington University School of Medicine in St. Louis

et al

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Ward, Rebecca A.; Mudd, Philip A.; Presti, Rachel M.; Spec, Andrej; and et al, ,"Harnessing the potential of
multiomics studies for precision medicine in infectious disease." Open Forum Infectious Diseases.,. .
(2021).
https://digitalcommons.wustl.edu/open_access_pubs/10962

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact scales@wustl.edu.

Open Forum Infectious Diseases
REVIEW ARTICLE

Harnessing the Potential of Multiomics Studies for
Precision Medicine in Infectious Disease
Rebecca A. Ward,1, Nima Aghaeepour,2,3,4 Roby P. Bhattacharyya,1,5 Clary B. Clish,5, Brice Gaudillière,2,3, Nir Hacohen,5,6 Michael K. Mansour,1,7
Philip A. Mudd,8, Shravani Pasupneti,9,10, Rachel M. Presti,11,12, Eugene P. Rhee,13 Pritha Sen,1,5,7,14 Andrej Spec,11, Jenny M. Tam,7,15,
Alexandra-Chloé Villani,5,7,14, Ann E. Woolley,16 Joe L. Hsu,9,10 and Jatin M.Vyas 1,7,

The field of infectious diseases currently takes a reactive approach and treats infections as they present in patients. Although certain
populations are known to be at greater risk of developing infection (eg, immunocompromised), we lack a systems approach to define the true risk of future infection for a patient. Guided by impressive gains in “omics” technologies, future strategies to infectious
diseases should take a precision approach to infection through identification of patients at intermediate and high-risk of infection
and deploy targeted preventative measures (ie, prophylaxis). The advances of high-throughput immune profiling by multiomics approaches (ie, transcriptomics, epigenomics, metabolomics, proteomics) hold the promise to identify patients at increased risk of infection and enable risk-stratifying approaches to be applied in the clinic. Integration of patient-specific data using machine learning
improves the effectiveness of prediction, providing the necessary technologies needed to propel the field of infectious diseases medicine into the era of personalized medicine.
Keywords. high-throughput technologies; infectious diseases; invasive fungal infections; systems immunology.
Infectious diseases (ID) physicians currently take a reactive approach in which we provide diagnostic and therapeutic advice on
patients with established infection. For example, Staphylococcus
aureus bacteremia is commonly encountered in inpatient settings. Although S aureus colonization and unsterile techniques
contribute to incidents of infection, there is clearly a role for
host factors in modulation of potential infection and disease
severity. The most common conditions that portend increased
risk for S aureus bacteremia are diabetes, intravenous drug use,
presence of central lines in patients requiring dialysis, cancer
chemotherapy, and corticosteroid use [1]. The underlying assumption is that bacteremia in this patient population cannot
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be accurately predicted, and therapeutic approaches are purely
reactive—treatment begins once the infection is established and
subsequently diagnosed. Unfortunately, this approach permits
widespread host damage from metastatic infection. Mortality
rates of 20%–40% have not changed in the past several decades, indicating that another approach is required [1]. The goal
for the field of ID in the 21st century should be to predict and
prevent infections in individual patients before they occur by
interrogating the patients’ immune system using multiomics
approaches. We have focused this review on the human immunology because the pathogen virulence and its impact has been
discussed elsewhere [2–4].
The need for a preemptive, risk-modifying approach to infections in ID is evident by the increasing number of high-risk
individuals due to advances in immunosuppression enabling
solid organ transplantation, chemotherapy for cancer, and
immunomodulatory therapeutics for autoimmune diseases
[5–9]. Evidence-based prophylaxis has reduced ID burden in
immune compromised patient (eg, Pneumocystis jirovecii pneumonia prophylaxis in human immunodeficiency virus [HIV]
patients with CD4 count of <200 cells/µL) [10]. However, total
T-cell counts do not account for specific effector T-cell populations of function, rendering this approach less precise. The
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S aureus, Pseudomonas aeruginosa) [22]. Although the idea of
personalized medicine is not new [23–26], technologies and bioinformatic approaches required to advance precision ID are
becoming available, and they are broadly applied to other fields
of medicine (eg, oncology).
POTENTIAL APPLICATION OF NEXT-GENERATION
TECHNOLOGIES IN THE CLINICAL SETTING

The immune system, one of the most complex and dynamic
biological systems in mammals, comprises diverse cell types
with varying functional states. Advances in high-throughput
profiling technologies, particularly single-cell omics platforms,
enable comprehensive characterization of immune components
at multiple scales. However, immunity is not merely a sum of its
components, and its behavior cannot be explained or predicted
solely by examining individual components. Therefore, systems biology approaches are essential for decoding the cellular
complexity, plasticity, and functional diversity of the immune
system. The emerging field of systems immunology enables
physician-scientists to better understand how the immune
system works in health and disease. Evaluation of clinical samples from known high-risk populations will empower future
risk-stratification of these populations and improve our ability
to deliver precision ID care. In addition, there is increasing evidence that local immunity provides a better window into immune responses than interrogating peripheral blood alone [27].
Interrogation of tissue resident memory cells has provided
significant insight into host responses and autoimmune diseases [28, 29]. Specifically, group 3 innate lymphoid cells and
T helper type 17 (Th17) cells may serve as key components of
tissue-resident memory cells acquired over time or elicited by
mucosal immunization that provides the host with enhanced
immunity against specific pathogens [30]. For example, LTRs
are often diagnosed with pulmonary infection, and therefore it
is critical to interrogate both systemic (ie, peripheral blood) and
local (ie, bronchoalveolar lavage fluid and lung biopsies) patient
samples to provide a fuller picture of immunity in response to
infection. Understanding local and systemic immune response
to infection at such a large-scale will enable refinement of future clinical assays and identification of relevant biomarkers
in susceptible patient populations. We envision an even closer
relationship between the ID/transplant physicians and oncologists/rheumatologists whereby ID physicians assists the treating
physician to select appropriate preventative strategies to avoid
life-threatening infections in at-risk patients.
Transcriptional Genomics

Development of systematic transcriptomic profiling and computational analyses have provided meaningful translational insights into various disease states and immunological response in
infections [31–37]. In the immune system, cell populations may
appear homogeneous, but analysis by single-cell sequencing
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future of ID medicine should predict and prevent infection
to avoid severe outcomes (eg, delay of therapy for underlying
processes and death). As a field, we are poised to leverage our
understanding of basic mechanisms in microbiology and immunology to learn how to risk-stratify patients and judiciously
deploy prophylactic antimicrobials to prevent infections using a
personalized medicine approach. In the near term, multiomics
studies can nominate specific molecular and cellular biomarkers
that can be measure using platforms currently deployed in patient care that will inform clinical decisions.
Medical mycology would greatly benefit from a precision approach to infection. Invasive fungal infections (IFIs) are dreaded
complications in immunocompromised populations, often carrying morality rates exceeding 50% [7, 11, 12]. Clinical data and
current literature implicate certain components of the immune
system as critical for swift clearance of fungal pathogens [13–
15]. However, the rules governing an inflammatory response
that contributes to the broad spectrum of clinical outcomes in
immunocompromised patients are not known. For example, individuals that receive a single- or double-lung transplant due
to end-stage pulmonary disease are at high-risk of developing
and succumbing to IFIs. The opportunistic fungal pathogen
Aspergillus fumigatus is the most commonly diagnosed fungal
pathogen in lung transplant recipients (LTRs), with lower incidence of infection by Mucor, Cryptococcus, and endemic fungi
(Histoplasma, Blastomyces, Coccidioides) [16, 17]. Furthermore,
A fumigatus colonization in these patients is associated with
accelerated chronic rejection [18, 19]. Understanding the underlying factors that predict development of fungal infection
in LTRs, and consequent rejection, will enable targeted preventative strategies (eg, vaccine, prophylactics, and/or alteration
in immunosuppression) in those at the greatest risk of poor
outcome.
Application of precision ID approaches benefits not only relatively small, highly defined cohorts (~4000 lung transplants
annually), but also larger, more heterogenous at-risk populations. Risk of infection in healthcare settings is amplified by the
need for invasive procedures (eg, insertion of central venous
catheters) leading to a break in the skin barrier and disruption
of commensal fungal populations [20, 21]. Candida spp is the
seventh most prominent pathogen in healthcare-associated infection ([HAI] <10% of all pathogens) and is a leading cause of
bloodstream infection (~22% of all pathogens) [22]. The observation that only a subset of at-risk patients develop candidemia
despite ubiquitous exposure indicates that host factors potently
modulate risk for this infection. Precision ID enables identification of patients at the highest risk of developing invasive
candidiasis so that a targeted prophylaxis approach will lead
to less morbidity and improved outcomes. It is not hard to imagine the benefits of a screen to identify hospitalized patients
at-risk of not only Candida infection, but also common bacterial pathogens contributing to HAIs (eg, Clostridium difficile,
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Figure 1. Workflow of transcriptional genomics from patient samples through single-cell ribonucleic acid sequencing (scRNA-seq) (A) and spatially resolved transcriptomics
(B). (A) Samples for scRNA-seq require dissociation of cells to ensure cells are not clumped together. Cells are sorted via antibody labeling to sort immune cells and
nonimmune cells. Samples undergo reverse transcription and complementary deoxyribonucleic acid amplification and profiled by sequencing through selected sequencing
technologies. These libraries often achieve 50 000 reads, providing detailed readouts of cell populations and substates, T-cell receptor (TCR) and B-cell receptor (BCR)
profiling, and underlying immune pathways in disease correlating with disease. (B) Tissue samples from infected regions, in this example lung tissue from lung transplant
recipients infected with Aspergillus, are snap frozen and sectioned into thin slices for spatial transcriptomics. After permeabilization, tissues are exposed to probes designed
to target specific RNA sequences followed by amplification that enables visualization of transcripts. Although methodology differs depending on the approach used, the
current example of these probes requires a ligation and crosslinking with a fluorescent tag. The resulting data allow analysis of transcripts in their spatial location. BAL,
bronchoalveolar lavage. (Printed with permission from Wolf N: 2021).

of ribonucleic acid (scRNA-seq) or examination of epigenetic
modifications can reveal cell-to-cell variability that may help
subpopulations of cells to rapidly adapt to evolving environments. Single-cell omics approaches, which result in quantitative and high-resolution snapshots of thousands to millions of
cells, interrogate human systems and underlying phenotypes
that may contribute to disease. Although it is less expensive,
bulk RNA-sequencing remains a lower powered approach because results generated reflect an average of all cells, which may
lead to critical changes in rare cell populations being overlooked.
The scRNA-seq analysis provides an unbiased, data-driven
way to systematically detect cellular states to reveal diverse simultaneous facets of cellular identity, from discrete cell types
to continuous dynamic transitions, which cannot be defined

by a handful of predefined markers or for which markers are
not yet known (Figure 1A). For example, scRNA-seq identified
rare epithelial cells, ionocytes, as the major source of cystic fibrosis transmembrane conductance regulator, which reshaped
the cystic fibrosis field [38]. In addition, a recent study demonstrated a monocyte phenotype, termed MS1, associated with
bacterial sepsis, which appears to be a hallmark of severe infections [39]. In previous studies, after the MS1 marker genes were
defined from scRNA-seq, there was evidence of its presence
in dozens of bulk transcriptional studies of sepsis with diverse
anatomic sources and microbiological causes, underscoring the
power of this approach.
Methodological adaptations such as T-cell receptor (TCR) or
B-cell receptor (BCR) repertoire profiling and cellular indexing
The Future of Infectious Diseases • OFID • 3
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Blood

Epigenomics

Although studies investigating genetic susceptibilities have
identified polymorphisms associated with infection (eg,
CARD9 mutations in IFIs), translation to the clinic does not
provide the whole story for risk and development of infection [53]. Common genetic traits do not produce consistent
4 • OFID • Ward et al

phenotype, but epigenetic modifications may bridge the gap
between phenotype and genes. Epigenetic modifications
alter gene expression and function through deoxyribonucleic
acid methylation and histone modification (eg, acetylation,
methylation, phosphorylation) [54]. Methodology to interrogate epigenomic changes utilize chromatin conformation
studies (eg, assay for transposase-accessible chromatin using
sequencing [ATAC-seq]) and histone modification profiling
(eg, chromatin immunoprecipitation) of clinical samples
(Figure 2) [55, 56]. Longitudinal studies that examine epigenetic modifications paired with scRNA-seq in high-risk patients may provide a roadmap to infection susceptibility and
ability to effectively clear pathogens. Epigenetic-based treatments are being explored in the context of HIV infections,
leading to preclinical and clinical trials for combination antiretroviral therapy [57, 58].
Historically, immune memory has been considered a function of the adaptive immune system (eg, T cells and B cells),
providing highly specific, long-lasting protection against invaders. Trained immunity is the concept of long-term functional reprogramming (namely, through epigenetic processes)
in early immune responders, also known as innate immune cells
(eg, neutrophils, monocytes, dendritic cells) [59]. Interaction
with these innate cells and a pathogen leads to altered response
during a second challenge with the same pathogen, contributing to innate-mediated short-term (ranging from 3 months to
1 year) protection against foreign invaders [59]. Histone methylation or acetylation are hallmarks of trained immunity in innate immune cells after stimulation with the fungal cell wall
carbohydrate β-1,3-glucan, a major component of Candida spp
[60–62]. Expansion of these studies into individuals with an elevated risk of infection may provide insights into novel preventative and therapeutic strategies to preemptively treat infections.
Metabolite Profiling

Metabolomics systematically quantifies metabolites in biological samples. These metabolites are derived from metabolic processes as well as complex biological interactions
within an organism. Clinical metabolomics detects the direct result generated by a biochemical response to a variety
of factors, including invading pathogens. The benefit of metabolite profiling is well demonstrated in the fields of cardiovascular disease, kidney disease, cancer metabolism, and
emerging in the field of ID [63–71]. Identification of circulating metabolites offers biomarker profiles that precede disease and track severity of disease. Technology platforms for
metabolic profiling typically utilize mass spectrometry (MS)
coupled with chromatographic separation (including liquid
chromatography and gas chromatography) and/or nuclear
magnetic resonance spectroscopy (NMR) [72, 73]. Because
there is ample diversity of metabolites, priority should be
made to process through complementary detection methods.
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of transcriptomes and epitopes by sequencing (CITE-seq) further increase the power of scRNA-seq. T-cell responses are essential to adaptive immunity to pathogens, including in IFIs.
For example, investigations in patients with HIV demonstrate
that a loss of T-cell immunity is closely tied to incidence of
cryptococcal meningitis [40–42]. Impaired T-cell responsiveness in other immunologically vulnerable populations have also
been observed in invasive Aspergillus and Candida infections
[43, 44]. In addition, the importance of B cells in ID has been
well documented in viral and bacterial infections, including
severe acute respiratory syndrome coronavirus 2, Klebsiella,
and Haemophilus influenzae [45–48]. The RNA-seq paired
with TCR or BCR repertoire analyses enables investigators to
interrogate expansion of T- and B-cell populations in disease.
In addition to these paired receptor analyses, CITE-seq, which
has been implemented in large-scale translational human immunology projects, enables simultaneous single-cell measurements of a predefined array of surface proteins and unbiased
gene expression [49]. The CITE-seq utilizes oligonucleotide
barcoded antibodies to quantitate protein expression through
flow cytometry measurements in tandem with messenger RNA
information provided my RNA-seq. Coupled with scRNA-seq,
these paired analyses provide a comprehensive look at immune
cells and tissues in disease.
Although scRNA-seq provides ample information about the
transcriptome in different cell populations, there is a loss of spatial data due to the required step of tissue dissociation. Through
advances in sequencing and imaging technologies, understanding expression of transcripts at the single-cell level in their
spatial layout provides better understanding within the distinct
microenvironment in infected regions and tissues (Figure 1B).
Numerous novel spatial transcriptomics approaches have been
reviewed previously [37, 50]. Additional complementary approaches such as multiplexed cytometric imaging (CODEX)
and in situ hybridization (RNAscope) may be used to improve
power of spatial transcriptomics [37, 51, 52]. A key advantage
to spatial transcriptomics is the ability to determine the impact
of local immune response in tissue, with temporal resolution. In
infection, development of a granuloma occurs during infection
to contain pathogens. Use of spatial transcriptomics of these
granulomas may provide insight into the molecular and cellular
mechanisms that govern pathogen containment. Thus, complementary scRNA-seq and spatial transcriptomics approaches
may provide ample information on host-pathogen responses
during infections and insights into prognosis.
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Figure 2. Epigenomic approaches utilizing clinical local (eg, lung tissue and bronchoalveolar lavage [BAL]) and systemic (eg, blood) samples. (A) Assay for transposaseaccessible chromatin using sequencing (ATAC-seq) measures chromatin conformation differences. The hyperactive transposase Tn5 loaded with a next-generation sequencing
library enables fragmentation of open chromatin regions. These fragments are amplified and sequenced to provide physician-scientists with accessible chromatin regions
at the single-cell level. (B) Histone modifications profiling through chromatin immunoprecipitation (ChIP) is an antibody-based technology that selectively enriches deoxyribonucleic acid (DNA)-binding proteins and their respective DNA targets (eg, histone modifications by methylation or acetylation). The DNA and its associated proteins on
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which removes remaining cellular debris. Although there are multiple downstream analyses that can be run on ChIP precipitates, sequencing after DNA purification provides
information on genome-wide binding in health and disease. (Printed with permission from Wolf N: 2021).

Liquid chromatography-MS, which has emerged as the workhorse for large-scale metabolomics, enables quantification
of a broad range of metabolites including lipids, sugars, organic acids, amino acids, amines, nucleotides, bile acids, and
acylcarnitines based on the detection method used (Figure 3).
Although there are hundreds of known compounds through
reference libraries, follow-up protocols (including NMR and
other MS approaches) are necessary to identify thousands of
unknown peaks. One barrier to keep in mind with respect
to comprehensive metabolomic profiling is the dynamic nature of metabolism and metabolite signatures, which requires
immediate processing to accurately dissect patient profiles.
Furthermore, an advantage of metabolomics is the ability to
identify metabolites from small sample volumes (as little as
10 µL), contributing to the potential to provide early clinical

measurements leading to preventative strategies and treatments of disease.
It has become evident that immune cells rely on changes in
cellular metabolism to mount effective antimicrobial responses,
with glucose metabolism being a central player in immune cell
function, although data from actively infected human patients
remain limited [74]. In recent studies, researchers have demonstrated the role of metabolism in trained immunity to fungal
pathogens. Emerging data suggest that an increase in glycolysis and glutaminolysis used in the tricarboxylic acid cycle and
a corresponding decrease in oxidative phosphorylation are
important to the host defense against fungal pathogens [60,
75–77]. It is unfortunate that these studies primarily utilize ex
vivo stimulation of peripheral blood samples from healthy individuals. Expansion of large-scale, nontargeted metabolomics
The Future of Infectious Diseases • OFID • 5
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Interrogation of the metabolome loops back to the patient by identification of metabolic biomarkers of disease. (Printed with permission from Wolf N: 2021).

in high-risk patient populations is warranted. In limited studies
into metabolic changes in organ transplantation, researchers
identified an increase in glycolysis during transplant rejection,
which provides rapid adenosine triphosphate generation and
biosynthetic intermediates that support anabolic processes [78,
79]. Expansion of these data in primary clinical samples (both
systemic and locally) will provide novel monitoring strategies
for LTRs for rejection and development of IFIs.
Considerations for timing of clinical sample collection, particularly in ID medicine, is critical and further studies are needed.
In sepsis, metabolism rapidly changes throughout progression
of disease. Metabolic profiles differentiated patients who developed sepsis in adults admitted to the intensive care unit due to
traumatic injury [80]. Thus, these profiles could be applied to
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precision medicine approaches to identify patients most likely
to develop infection. Understanding longitudinal changes in
infection would enable clinicians to better predict the course
of disease. Furthermore, examination of the metabolome may
be applied to predict drug response. Investigation into novel
therapeutics and treatment strategies is essential with the emergence of more multidrug-resistant pathogens. Metabolomics
could be applied as an indicator for the pathogen, which currently relies on culture methods. A study of fungal infections in
neonates identified elevations of the amino acid, serine, during
active infection, which declined after antifungal therapy, when
compared with healthy controls [81]. Thus, large-scale metabolomics to identify diagnostic biomarkers, monitor progress of
infection, and development of new treatment is warranted.
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Proteomic Analyses

The proteome encompasses the overall protein content within a
cell, including protein-protein interactions and posttranslational
modifications (eg, phosphorylation) at a particular time point.
Measurements of global protein expression within cells or tissues
encompass a variety of approaches ranging from targeted, highdimensional panels to large-scale, unbiased techniques. Protein
phosphorylation is an essential posttranslational modification
that enables regulation of most biological processes [82–86]. In
one sense, the recipe for a successful immune response to an
invading pathogen is timely activation and inhibition of distinct
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The Future of Infectious Diseases • OFID • 7

Downloaded from https://academic.oup.com/ofid/article/8/11/ofab483/6375269 by 81392966 user on 07 December 2021

signaling pathways in immune cells to provide efficient antimicrobial effect without inducing excessive tissue damage. Correlating
these changes by monitoring phosphorylation status of key intracellular signaling molecules with clinical outcome may provide critical insights into the mechanism of protective immunity.
Mass cytometry-based (ie, cytometry by time of flight [CyTOF])
phosphoproteomics methodology provides a platform to globally study activation or inhibition of multiple signaling pathways
across the entire immune system with single-cell resolution [87].
Indeed, novel insights into TLR signaling and T-cell activation
have been uncovered by phosphoproteomics analysis (Figure 4A)

PRECISION MEDICINE IN INFECTIOUS DISEASES

Transcriptional expression, epigenetic forms, metabolites, and
protein expression are all interwoven to directly impact immune responses in disease. Individually, high-throughput
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omics approaches provide a window into immune responses
and phenotypes that portend increased risk of infection and
may foretell clinical course. Given the complex interplay among
different aspects of the immune system, combining multiomics
modalities into a computational framework increases predictive power and reveals crosstalk between different layers of biological profiling (Figure 5). However, merging transcriptomic,
epigenomic, metabolomic, and proteomic features into predictive models will require continued development of new statistical tools designed to study high-dimensional datasets. Recent
advances in bioinformatic processes overcome many analytic challenges that previously prevented the development of
models to accurately predict patient outcomes [86, 102, 103].
Regularized regression methods such as the Elastic Net algorithm have proven useful for selection of key predictive features
and development of clinical models [104]. A stacked generalization method that combines multiple regularized regression
models developed from individual omic datasets has also been
recognized as a valuable approach for data integration and can
improve overall model performance [86]. This approach has
been successfully implemented for the prediction of various
clinical outcomes, including development of insulin resistance [105], onset of spontaneous labor [106], survival of persons with pancreatic cancer [107], and severity of COVID-19
infections [85]. Furthermore, development of effective visualization methods for these integrated machine learning models
improves understanding of results [108, 109]. Taken together,
these analytic approaches provide mechanistic information regarding the crosstalk between various biological systems that
could not otherwise be identified from each assay individually.
Implementation of precision ID medicine requires immune
profiling of well phenotyped human cohorts, particularly patients with known risk factors (eg, solid organ transplantation,
cancer, invasive procedures). Although recent advances have
improved cost effectiveness and availability of these omics technologies, there is still a heavy burden on resources. To realize the
full potential of these technologies, there needs to be significant
reduction in cost of processing and analyzing each sample to
ensure access to all patients. Major funding agencies acknowledge this need as demonstrated by new funding mechanisms
through the National Institutes of Health (Human Immunology
Project Consortium) and European Research Council (Horizon
Program) [110, 111]. Further multiomics studies are warranted
to make precision ID a clinical reality.
CONCLUSIONS

Translational systems immunology provides the framework
to shift from reactive to proactive precision ID medicine,
improving the quality of life and dampening complications
in high-risk populations (Figure 5). Although many omics
approaches have been used to understand host response to
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[88, 89]. Insights into the distribution and activation or inhibition
of intracellular signaling pathways by targeting phosphorylation
states of known signaling molecules in immune cells provides
mechanistic understanding of disease states and infection [85].
Targeted profiling via the CyTOF platform enables investigators to
tailor a panel of ~50 markers to dissect specific cell subsets and activation states of different proteins. For example, the CyTOF panel
examining differences in innate immunity from invasive candidiasis HAI may include proteins associated with Candida immunity,
such as iNOS, Arg1, Ym1, Ym2, IL-4, and Egr2 [90–92].
Secretion of proteins to the external environment is critical
in maintaining cell-cell communication and recruitment of
immune cells in response to pathogens. These secreted proteins include hormones, cytokines, chemokines, and growth
factors. Measurement of these secreted proteins (secretome)
can be done through a targeted multiplex array approach (eg,
multianalyte assay). Multiplex assays allow for simultaneous
detection and quantification of multiple proteins (Figure 4B).
Stimulation of peripheral blood mononuclear cells (PBMCs)
or tissues from patients with a pathogen may provide insights
in the variations of the secretome in patients with high-risk of
infection compared with healthy controls. Multianalyte assays
have been used to investigate numerous infections [93–96].
Although a targeted approach may provide single-cell resolution and insights into known immune factors, application of
large-scale, unbiased proteomic approaches contributes to identification of novel proteins associated with disease. Furthermore,
this type of approach may identify biomarkers of disease and
clinical severity. The SomaScan assay developed by SomaLogic
is an aptamer-based approach that measures up to 7000 unique
human proteins (Figure 4C). Although it is optimized for a set
of core sample types (plasma, serum, urine), the SomaScan assay
sample source has the ability to interrogate noncore sample
sources (bronchoalveolar lavage, cell-conditioned media, cerebrospinal fluid, exosomes, sputum, tissue homogenates).
Aptamer-based proteomics is widely used in neurodegenerative disease, cardiovascular diseases, and infections [97–100].
Indeed, use of Slow Off-rate Modified Aptamers (SOMAmers)
in the SomaScan assay and RNA-seq was used to identify tissuespecific clinical markers of heart, kidney, liver, and skeletal muscle
damage in patients with coronavirus disease 2019 (COVID-19)
[101]. These biomarkers can be used upon presentation to the
hospital using blood samples to detect COVID-19-driven organ
damage. Taken together, these proteomic approaches identify
activated pathways and biomarkers of infection critical for implementation of precision ID medicine into clinical practice.
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Figure 5. Workflow of reactive (A) and precision (B) infectious diseases (ID) medicine. A precision approach would enable clinicians to use preventative strategies, leading to
fewer infections and infectious complications, including targeted prophylaxis or therapies that enhance immunity to specific pathogens. (C) Incorporation of multiomics approaches
into an integrative machine learning model more accurately predicts clinical outcomes. Multiomics include transcriptomics (bulk or single-cell ribonucleic acid [RNA] sequencing
[with or without paired analyses] and spatial transcriptomics), epigenomics (chromatin immunoprecipitation [ChIP] and assay for transposase-accessible chromatin using sequencing
[ATAC-seq]), metabolomics (liquid chromatography tandem mass spectrometry [LC-MS] and one-dimensional proton nuclear magnetic resonance spectroscopy [NMR]), and proteomics (cytometry by time-of-flight [CyTOF], aptamer-based methods [SomaScan], and multianalyte array). Combining these multiomics methodologies across longitudinal samples of
local and peripheral immune responses provides insight into relevant pathways and predicts clinical outcomes in disease. (Printed with permission from Wolf N: 2021).
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prophylactic antibiotic strategies.
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